EA200870233A1 - Производные тиадиазола для лечения нейродегенеративных заболеваний - Google Patents

Производные тиадиазола для лечения нейродегенеративных заболеваний

Info

Publication number
EA200870233A1
EA200870233A1 EA200870233A EA200870233A EA200870233A1 EA 200870233 A1 EA200870233 A1 EA 200870233A1 EA 200870233 A EA200870233 A EA 200870233A EA 200870233 A EA200870233 A EA 200870233A EA 200870233 A1 EA200870233 A1 EA 200870233A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disease
treatment
derivatives
tiadiazole
neurodegenerative diseases
Prior art date
Application number
EA200870233A
Other languages
English (en)
Other versions
EA018067B1 (ru
Inventor
Герард Гриффиун
Кристель Мари Эдит Купе
Хейн Роже Дюамель
Стефан Вера
Эллен Гомме
Неле Ван Дамм
Ингрид Ван Дер Аувера
Марлен Локс
Том Ван Дорен
Тине Декрей
Original Assignee
Нв Реминд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нв Реминд filed Critical Нв Реминд
Publication of EA200870233A1 publication Critical patent/EA200870233A1/ru
Publication of EA018067B1 publication Critical patent/EA018067B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение предусматривает специфические замещенные производные 1,2,4-тиадиазола для применения при лечении α-синуклеинопатий, таких как болезнь Паркинсона, диффузионная болезнь телец Леви, травматическое повреждение мозга, боковой амиотрофический склероз, болезнь Неймана-Пикка, синдром Галлервордена-Спатца, синдром Дауна, нейроаксональная дистрофия, множественная системная атрофия и болезнь Альцгеймера.
EA200870233A 2006-02-07 2007-02-07 Производные тиадиазола для лечения нейродегенеративных заболеваний EA018067B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0602335.2A GB0602335D0 (en) 2006-02-07 2006-02-07 Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases
PCT/EP2007/001022 WO2007090617A2 (en) 2006-02-07 2007-02-07 Thiadiazole derivatives for the treatment of neuro degenerative diseases

Publications (2)

Publication Number Publication Date
EA200870233A1 true EA200870233A1 (ru) 2009-02-27
EA018067B1 EA018067B1 (ru) 2013-05-30

Family

ID=36101115

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870233A EA018067B1 (ru) 2006-02-07 2007-02-07 Производные тиадиазола для лечения нейродегенеративных заболеваний

Country Status (16)

Country Link
EP (1) EP1981504B1 (ru)
JP (1) JP5283511B2 (ru)
CN (1) CN101378757B (ru)
AT (1) ATE474579T1 (ru)
AU (1) AU2007213954B2 (ru)
BR (1) BRPI0707700B8 (ru)
CA (1) CA2641453C (ru)
DE (1) DE602007007890D1 (ru)
DK (1) DK1981504T3 (ru)
EA (1) EA018067B1 (ru)
ES (1) ES2348999T3 (ru)
GB (1) GB0602335D0 (ru)
HK (1) HK1122989A1 (ru)
PL (1) PL1981504T3 (ru)
PT (1) PT1981504E (ru)
WO (1) WO2007090617A2 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090188A1 (es) * 2007-03-15 2009-03-20 Novartis Ag Compuestos heterociclicos como moduladores de la senda de hedgehog
US20090325964A1 (en) * 2008-05-23 2009-12-31 Wyeth Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression
EP2307391B1 (de) * 2008-06-27 2014-01-01 Bayer CropScience AG Thiadiazolyloxyphenylamidine und deren verwendung als fungizide
KR101712684B1 (ko) 2009-05-04 2017-03-06 바스프 코포레이션 희박 연소 가솔린 엔진을 위한 ｔｗｃ의 개선된 희박 ｈｃ 전환
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
ES2540956T3 (es) * 2011-07-01 2015-07-15 Remynd Nv Derivados de 1,2,4-tiadiazol-5-ilpiperazina útiles en el tratamiento de enfermedades neurodegenerativas
CN103649062B (zh) * 2011-08-17 2015-10-07 瑞敏德股份有限公司 用于治疗tau病变如阿尔茨海默病的哌嗪噻唑衍生物
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
MY186311A (en) 2013-12-20 2021-07-08 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
EP3119774A1 (en) * 2014-03-17 2017-01-25 reMynd NV Oxadiazole compounds
JP7178831B2 (ja) 2018-08-30 2022-11-28 日本特殊陶業株式会社 基板保持部材

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060472A (en) 1998-04-06 2000-05-09 Apotex Inc. Thiadiazole compounds useful as inhibitors of H+ /K+ atpase
WO2002083863A2 (en) * 2001-04-17 2002-10-24 Sepracor, Inc. Thiazole and other heterocyclic ligands and use thereof
MXPA06001845A (es) * 2003-08-21 2006-05-04 Pfizer Prod Inc Compuestos para el tratamiento de trastornos neurodegenerativos.
US7232820B2 (en) * 2004-04-01 2007-06-19 Pfizer Inc Thiadiazole-amine compounds for the treatment of neurodegenerative disorders
DE102004032567A1 (de) * 2004-07-05 2006-03-02 Grünenthal GmbH Substituierte 1-Propiolyl-piperazine

Also Published As

Publication number Publication date
HK1122989A1 (en) 2009-06-05
JP5283511B2 (ja) 2013-09-04
CA2641453A1 (en) 2007-08-16
PL1981504T3 (pl) 2010-12-31
BRPI0707700B1 (pt) 2020-08-04
CN101378757B (zh) 2012-08-01
JP2009526000A (ja) 2009-07-16
WO2007090617A2 (en) 2007-08-16
CA2641453C (en) 2013-07-30
BRPI0707700B8 (pt) 2022-12-20
EP1981504A2 (en) 2008-10-22
AU2007213954A1 (en) 2007-08-16
DE602007007890D1 (de) 2010-09-02
GB0602335D0 (en) 2006-03-15
CN101378757A (zh) 2009-03-04
PT1981504E (pt) 2010-10-13
DK1981504T3 (da) 2010-11-08
WO2007090617A3 (en) 2008-02-28
BRPI0707700A2 (pt) 2011-05-10
EA018067B1 (ru) 2013-05-30
ATE474579T1 (de) 2010-08-15
EP1981504B1 (en) 2010-07-21
AU2007213954B2 (en) 2011-09-22
ES2348999T3 (es) 2010-12-21

Similar Documents

Publication Publication Date Title
EA200870233A1 (ru) Производные тиадиазола для лечения нейродегенеративных заболеваний
BRPI0818799A2 (pt) Composições para o tratamento da doença de parkinson
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
ZA200802762B (en) Pharmaceutical compositions for the treatment of inner ear disorders
ES2616789T8 (es) Inhibidores de tirosina cinasa de Bruton
EP1940373B8 (en) 1-fluoro-1-deoxy-scyllo-inositol for the treatment of alzheimer's disease
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
EP2037739A4 (en) POSITIVE ALLOSTERIC EFFECTORS OF BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MY150558A (en) A pharmaceutical composition comprising rebamipide
HK1124863A1 (en) Inhibitors of sodium glucose co-transporter 2 and methods of their use
TN2010000155A1 (en) Organic compounds
WO2009019295A3 (en) Phenyl- and benzylthiazolylpiperazine derivatives for the treatment of neurodegenerative diseases
MX2010013451A (es) Composiciones farmaceuticas que comprenden derivados de aminociclohexano.
NL1033562A1 (nl) Tetrahydropyridoazepine-8-onen en verwante verbindingen voor de behandeling van schizofrenie.
MX340564B (es) Isoformas de neurregulina solubles activas modificadas post-traduccionalmente.
WO2010000089A8 (en) Stat3 and tyk2 as drug targets for neurodegenerative diseases
WO2007017146A3 (en) Use of collismycin and derivatives thereof as oxidative stress inhibitors
DE502007002949D1 (de) Proteinbindende methotrexat-derivate und diese enthaltende arzneimittel
WO2009134668A3 (en) 4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators
ATE450273T1 (de) Proliferationshemmendes arzneimittel
WO2022204362A3 (en) Compositions and methods for treating a neurodegenerative or developmental disorder
FR2918281B1 (fr) Medicament pour le traitement de la maladie de parkinson.
WO2008014232A3 (en) Pharmaceutical formulations for the treatment of alzheimer's disease
WO2009140649A3 (en) Rab3b for the treatment and prevention of parkinson's disease

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM